(en)The present invention relates to compounds of formula (I)

ArCH.sub.2 R.sup.1 (I)

or a monomethyl or a monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 30 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is a pyrene or substituted pyrene ring system; R 1 contains not more than eight carbon carbon atoms and is a group ##STR1## wherein m is 0 or 1; R 5 is hydrogen;
R 6 and R 7 are the same or different and each is hydrogen or C 1-3 alkyl optionally substituted by hydroxy;
R 8 and R 9 are the same or different and each is hydrogen or C 1-3 alkyl; ##STR2## is a five- or six-membered saturated carbocyclic ring; R 10 is hydrogen, methyl or hydroxymethyl;
R 11 , R 12 and R 13 are the same or different and each is hydrogen or methyl;
R 14 is hydrogen, methyl, hydroxy, or hydroxymethyl.

1.ApplicationNumber: US-10227587-A
1.PublishNumber: US-4820873-A
2.Date Publish: 19890411
3.Inventor: BAIR; KENNETH W.

4.Inventor Harmonized: BAIR KENNETH W(US)

5.Country: US
6.Claims:
(en)The present invention relates to compounds of formula (I)

ArCH.sub.2 R.sup.1 (I)

or a monomethyl or a monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 30 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is a pyrene or substituted pyrene ring system; R 1 contains not more than eight carbon carbon atoms and is a group ##STR1## wherein m is 0 or 1; R 5 is hydrogen;
R 6 and R 7 are the same or different and each is hydrogen or C 1-3 alkyl optionally substituted by hydroxy;
R 8 and R 9 are the same or different and each is hydrogen or C 1-3 alkyl; ##STR2## is a five- or six-membered saturated carbocyclic ring; R 10 is hydrogen, methyl or hydroxymethyl;
R 11 , R 12 and R 13 are the same or different and each is hydrogen or methyl;
R 14 is hydrogen, methyl, hydroxy, or hydroxymethyl.

7.Description:
(en)This application is a continuation, of application Ser. No. 661,801, filed Oct. 17, 1984, and now abandoned which is a continuation-in-part of application Ser. No. 499,330, filed May 31, 1983 and now abandoned.


The present invention relates to polycyclic aromatic alkanol derivatives which have been found to have biocidal activity. More specifically the invention concerns aminoalkanol derivatives containing a polycarbocyclic aromatic ring system, methods for the synthesis thereof, pharmaceutical formulations thereof, novel intermediates therefor, pharmaceutical formulations thereof and the use thereof as biocidal agents, particularly antitumor agents.
Accordingly, in a first aspect, the present invention provides a compound of the formula (I):

ArCH.sub.2 R.sup.1 (I)

or a monomethyl or monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 30 carbon atoms in total); ethers, esters thereof; acid addition salt thereof;
wherein
Ar is a pyrene ring optionally substituted by one or two substituents (the substituents will contain not more than four carbon atoms in total when taken together being the same or different and are selected from halogen; cyano; C 1-4 alkyl or C 1-4 alkoxy, each optionally substituted by hydroxy or C 1-2 alkoxy; halogen substituted C 1-2 alkyl or C 1-2 alkoxy; a group S(O) n R 2 wherein n is an integer 0, 1 or 2 and R 2 is C 1-2 alkyl optionally substituted by hydroxy or C 1-2 alkoxy; or the pyrene ring is optionally substituted by a group NR 3 R 4 containing not more than 5 carbon atoms wherein R 3 and R 4 are the same or different and each is a C 1-3 alkyl group or NR 3 R 4 forms a five- or six-membered heterocyclic ring optionally containing one or two additional heteroatoms);
R 1 contains not more than eight carbon atoms and is a group ##STR3## wherein m is 0 or 1;
R 5 is hydrogen;
R 6 and R 7 are the same or different and each is hydrogen or C 1-3 alkyl optionally substituted by hydroxy;
R 8 and R 9 are the same or different and each is hydrogen or C 1-3 alkyl; ##STR4## is a five- or six-membered saturated carbocyclic ring; R 10 is hydrogen, methyl or hydroxymethyl;
R 11 , R 12 and R 13 are the same or different and each is hydrogen or methyl;
R 14 is hydrogen, methyl, hydroxy, or hydroxymethyl.
Suitably ArCH 2 R 1 or a monomethyl or monethyl ether thereof contains not more than 28 carbon atoms in total.
Ar is suitably 1-pyrenyl, ##STR5## suitably m is 0, suitably R 1 is ##STR6## wherein R 16 is CH 2 OH, CH(CH 3 )OH or CH 2 CH 2 OH,
R 17 is hydrogen, C 1-3 alkyl or CH 2 OH;
R 18 is hydrogen or methyl.
Preferably R 16 is CH 2 OH or CH(CH 3 )OH; R 17 is hydrogen, methyl, ethyl or CH 2 OH.
Most preferably R 1 is a diol of the structure ##STR7## wherein R 19 is hydrogen or methyl and R 20 is hydrogen, methyl or ethyl, preferably methyl. Acid addition salts included within the scope of the present invention are those of compound of formula (I) and ethers and esters thereof.
Esters and nonpharmaceutically useful acid addition salts of the compounds of the formula (I) are useful intermediates in the preparation and purification of compounds of the formula (I) and pharmaceutically useful acid addition salts thereof, and are therefore within the scope of the present invention. Thus, acid addition salts of the compounds of the formula (I) useful in the present invention include but are not limited to those derived from inorganic acids, such as hydrochloric, hydrobromic, sulfuric and phosphoric acids, and organic acids such as isethionic (2-hydroxyethylsulfonic), maleic, malonic, succinic, salicylic, tartaric, lactic, citric, formic, lactobionic, pantothenic, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, naphthalene-2-sulfonic, and ascorbic acids, and amino acids such as glycine.
Acid addition salts particularly useful as biocidal agents are those that are pharmacologically and pharmaceutically acceptable. Thus, suitable acid addition salts include but are not limited to those derived from hydrochloric, methanesulfonic, ethanesulfonic, lactic, citric and isethionic acids.
The preferred pharmacologically and pharmaceutically acceptable acid addition salts are those that are soluble in solvents suitable for parenteral administration, for example, hydrochlorides, methanesulfonates and isethionates. Esters of compounds of formula (I) are derived from acids known to those skilled in the art to be suitable for ester formation, and are conveniently those derived from C 1-6 alkanoic acids or alkanoic acid derivatives, for example acetic acid, propionic acid, n-butyric acid and iso-butyric acid. The esters may be formed from all or only some of the hydroxy groups contained in the compounds of formula (I). Specific compounds within the scope of formula (I) include;
2-Methyl-2-((1-pyrenylmethyl)amino)propanol,
3-((1-Pyrenylmethyl)amino)propanol,
3-Methyl-2-((1-pyrenylmethyl)amino)butanol,
2-Ethyl-2-((1-pyrenylmethyl)amino)-1,3-propanediol,
2-((1-Pyrenylmethyl)amino)butanol,
2-((1-Pyrenylmethyl)amino)propanol,
1-((1-pyrenylmethyl)amino)-2-propanol,
2-Methyl-2-((1-pyrenylmethyl)amino)-1,3-propanediol,
1-((1-Pyrenylmethyl)amino)-2-butanol,
2-Hydroxymethyl-2-((1-pyrenylmethyl)amino)-1,3-propanediol,
2-((1-Pyrenylmethyl)amino)-1,3-propanediol,
2-(((1-Pyrenylmethyl)amino)methyl)-2-propanol,
2-((1-Pyrenylmethyl)amino)ethanol,
4-((1-Pyrenylmethyl)amino)-2-butanol,
2-(((6-Bromo-1-byrenyl)methyl)amino)-2-methyl-1,3-propanediol and 2-(((8-Bromo-1-pyrenyl)methyl)amino)-1,3-propanediol,
2-Methyl-2-((4-pyrenylmethyl)amino)-1,3-propanediol,
(+-)(2R*,3S*)-2-((1-Pyrenylmethyl)amino)-2-methyl-1,3-butanediol,
2-Ethoxymethyl-2-((1-pyrenylmethyl)amino)-1,3-propanediol,
3-Methoxy-2-methyl-2-((1-pyrenylmethyl)amino)-1-propanol,
1α,2β,3α)-2-((1-Pyrenylmethyl)amino)-1,3-cyclohexanediol,
2-(((3-Ethyl-1-pyrenyl)-methyl)amino)-2-methyl-1,3-propanediol,
2-Isopropyl-2-((1-pyrenylmethyl)amino)-1,3-propanediol and
2-(((8-Ethoxy-1-pyrenyl)methyl)amino)-2-methyl-1,3-propanediol;
ethers, esters thereof; acid addition salts thereof.
Of these specific examples of compounds of formula (I), the most preferred compound is 2-methyl-2-((1-pyrenylmethyl)amino)-1,3-propanediol; ethers, esters thereof; acid addition salts thereof.
The compounds of formula (I) and their ethers, esters, and salts thereof may be prepared by any method known in the art for the preparation of compounds of analogous structure. Thus, the compounds of formula (I) may, for example, be prepared by any of the methods defined below.
1. The reduction of a compound of formula (II) ##STR8## Wherein R 1 -R 4 are as hereinbefore defined or an appropriately protected derivative thereof followed by deprotection where appropriate.
The conditions and reagents for such a reaction are well known to those skilled in the art, and any such conditions/reagents may be employed. The conversion of (II) or suitably protected derivatives thereof may be carried out by a reducing agent followed by deprotection if necessary. The reduction conveniently carried out by a metal hydride such as lithium aluminum hydride, sodium borohydride, sodium cyanoborohydride, or by catalytic hydrogenation, conveniently by hydrogen in the presence of a metal catalyst such as palladium or platinum, or equivalent reagent as outlined by J. March, Advanced Organic Chemistry, 2nd ed., pages 819-820, McGraw Hill, New York, 1977. The reduction is suitably carried out with the compound of formula (II) in solution in an inert solvent or mixture of solvents compatible with the reducing agent, at a non-extreme temperature, or example, between 0° and 80° C., conveniently at room temperature.
In the case of lithium aluminum hydride and like reagents, suitable solvents include ethers (for example tetrahydrofuran, diethyl ether and 1,2-dimethoxyethane) optionally in the presence of a hydrocarbon cosolvent (for example toluene, benzene or hexane).
In the case of sodium borohydride and like reagents, suitable solvents include alcohol (for example ethanol, methanol or isopropanol) optionally in the presence of a hydrocarbon cosolvent (for example toluene, benzene or hexane) or an ether cosolvent (for example diethylether or tetrahydrofuran).
In the case of sodium cyanoborohydride and like reagents, suitable solvents include those described for sodium borohydride and in the presence of an acid conveniently glacial acetic acid or ethanolic hydrochloric acid as outlined in, for example, R. Hutchins et al., Organic Preparations and Procedures International 11, 201 (1979).
In the case of catalytic hydrogenation, suitable solvents include alcohols (for example methanol and ethanol) optionally in the presence of a hydrocarbon cosolvent (for example toluene or benzene) or ether cosolvent (for example diethyl ether or tetrahydrofuran) optionally in the presence of an acid (for example glacial acetic acid or ethanolic hydrochloric acid) or in glacial acetic acid.
Protected derivatives of compounds of formula (II) are conveniently used when lithium aluminum hydride is employed as the reducing agent. Convenient protecting groups are compatible with the reducing agent utilized and are readily removed under nondestructive conditions, for example benzyl, tetrahydropyranyl and isopropylidene ethers.
It is often convenient not to isolate the compound of the formula (II) but to react a compound of the formula (III) with a compound of the formula (IV): ##STR9## wherein Ar and R 1 -R 4 are as defined in (I), and reduce the compound of the formula (II) so formed in situ. The rection of the compounds of the formulae (III) and (IV) is again suitably carried out using conditions and reagents which are well known to those skilled in the art, for example in the presence of an acid, such as a sulfonic acid, i.e. p-toluenesulfonic acid, in an appropriate inert solvent, such as an aromatic hydrocarbon, for suitably toluene, with azeotropic removal of water followed by treatment with the reducing agent in an appropriate solvent, suitable ethanol or methanol. Alternatively, (II) formed under equilibrium conditions in appropriate solvents can be reduced in situ with an appropriate reducing agent, suitably sodium cyanoborohydride.
The compound of formula (III) may be in the form of a protected aldehyde, for example an acetal, which liberates the aldehyde function under the reaction conditions.
In turn, a compound of formula (III) can be synthesized by reacting the appropriate polycyclic aromatic hydrocarbon with a formylating agent such as that generated by the reaction between SnCl 4 and Cl 2 CHOCH 3 or equivalent reagents, for example, according to the method of A. Reiche et al., Chem. Ber. 93, 88 (1960), or with other standard formylating reagents/procedures known to the art, for example, the Gatterman-Koch reaction (CO/HCl/AlCl 3 /CuCl), the Gatterman reaction (HCN/HCl/ZnCl 2 ), and the Vilsmeier reaction (POCl 3 /PhN(Me)CHO or POCl 3 /Me 2 NCHO) (J. March, vide supra pages 494-497).
The compounds of the formula (III) may also be prepared from an appropriate polycyclic aromatic hydrocarbon substituted by a suitable functional group such as CH 2 OH, CHBr 2 , CH 3 , COCH 3 , COOH, or CN, and converting this functional group to an aldehyde group by methods well known to those skilled in the art.
Where the polycyclic aromatic ring bears substituents, the compound of formula (III) may be prepared by a variety of methods known in the art of organic chemistry depending on the nature of the substituent on the polycyclic ring. For example, if the substituent(s) is a halogen, the starting materials may be prepared by direct treatment of the polycyclic aromatic hydrocarbon with a halogenating agent (e.g. Cl 2 , Br 2 , or SO 2 Cl 2 ) or directly by such routes as the Sandmeyer reaction (H. H. Hodgson, Chem. Rev. 40, 251 (1947). If the substituent(s) is alkyl, the polycyclic aromatic hydrocarbon may be reacted with the appropriate reagents under Friedel-Crafts reaction conditions (G. A. Olah, Friedel Crafts and Related Reactions, Vols. 1-3, Interscience, New York, NY, 1963-1965).
The compounds of the formula (IV) also may be prepared by methods known in the art, for example, by the reaction of compound NO 2 CH 2 R 2 with an appropriate aldehyde, conveniently acetaldehyde or formaldehyde (as in B. M. Vanderbilt and H. B. Hass, Ind. Eng. Chem. 32, 34 (1940)) followed by reduction (as outlined in J. March, vide supra, pages 1125-1126), conveniently by hydrogen and a metal catalyst (for example, a platinum containing catalyst) in an appropriate solvent, conveniently glacial acetic acid.
2. The reduction of a compound of the formula (V) ##STR10## wherein Ar and R 1 -R 4 are as hereinbefore defined and the hydroxy groups are optionally protected, followed by deprotection of the hydroxy groups where appropriate. The reduction may be carried out by standard reducing agents known for carrying out this type of reduction (as outlined in J. March, vide supra, page 1122), for example, a hydride reagent such as lithium aluminium hydride in an inert solvent, such as an ether, i.e. tetrahydrofuran, at a non-extreme temperature, for example, at between 0° and 100° C. and conveniently at the reflux temperature of the ether.
The compound of the formula (V) may be formed by the reaction of the appropriate acid (ArCOOH) or a suitable reactive acid derivative thereof as outlined in J. March, vide supra, pages 382-390) for example, an acid halide in an inert solvent, with an amine of the formula (IV) in which the hydroxy groups are optionally protected, for example, when the compound of the formula (IV) is a diol, by an isopropylidene group. The compound of the formula (V) so formed is suitably reduced in situ and deprotected if necessary to give a compound of formula (I). The compounds of the formula ArCOOH can be prepared by methods well known to those skilled in the art.
3. The reaction of a compound ArCH 2 L (wherein Ar is as hereinbefore defined and L is a leaving group), with a compound of the formula (IV) as hereinbefore defined. Suitable leaving groups are those defined by J. March, vide supra pages 325-331, and include halogens such as chlorine or bromine and sulfonic acid derivatives such as p-toluenesulfonate. The reaction is suitably carried out in an appropriate solvent, such as a dipolar aprotic solvent or alcohol at a non-extreme temperature, for example 50°-100°. The compounds of the formula ArCH 2 L can be prepared by methods well known to those skilled in the art.
There is therefore provided, as a further aspect of the invention, a method for the preparation of a compound of formula (I) comprising any method known for the preparation of analogous compounds, in particular those methods defined in (1) to (3) hereinabove.
The compounds of this invention have biocidal activity, e.g. are toxic to certain living cells which are detrimental to mammals, for example pathogenic organisms and tumor cells.
This toxicity to pathogenic organisms has been demonstrated by activity against viruses (e.g. Herpes simplex 1/vero), fungi (e.g. Candida albicans), protozoa (e.g. Eimeria tenella and Trichomonas vaginalis), bacteria (e.g. Mycoplasma smegmatis and Streptococcus pyogenes), and helminths (e.g. Nippostrongylus brasiliensis and Brugia pahangi). The antitumor activity of compounds of formula (I) has been demonstrated in a number of recognized screens and primarily by activity against ascitic P388/O leukemia.
Preferred compounds of the formula (I) are those which have antitumor activity. The activity against ascitic tumors, including P388/O, is evidenced by reduction of tumor cell number in mammals (for example, mice bearing ascitic tumors) and their consequent increase in survival duration as compared to an untreated tumor bearing control group. Antitumor activity is further evidenced by measurable reduction in the size of solid tumors following treatment of mammals with the compounds of this invention compared to the tumors of untreated control tumor bearing animals. Compounds of formula (I) are active against murine tumors such as lymphocytic leukemia P388/O, lymphocytic leukemia L1210, melanotic melanoma B16, P815 mastocytoma, MDAY/D2 fibrosarcoma, colon 38 adenocarcinoma, M5076 rhabdomyosarcoma and Lewis lung carcinoma.
Activity in one or more of these tumor tests has been reported to be indicative of antitumor activity in man (A. Goldin et al. in Methods in Cancer Research ed. V. T. DeVita Jr. and H. Busch, 16 165, Academic Press, New York 1979).
There are sublines of P388/O which have been made resistant to the following clinically useful agents: cytosine arabinoside, doxorubicin, cyclophosphamide, L-phenylalanine mustard, methotrexate, 5-fluorouracil, actinomycin D, cis-platin and bis-chloroethylnitrosourea. Compounds of this invention show potent activity against these drug-resistant tumors using the procedure for P388/O.
Compounds of formula (I) have also been found to be active against human tumor cells in primary cultures of lung, ovary, breast, renal, melanoma, unknown primary, gastric, pancreatic, mesothelioma, myeloma, and colon cancer. (As used herein "cancer" is to be taken as synonymous with "malignant tumor" or more generally "tumor" unless otherwise noted.) This is a procedure in which the prevention of tumor cell colony formation, i.e. tumor cell replication, by a drug has been shown to correlate with clinical antitumor activity in man (D. D. Von Hoff et al., Cancer Chemotherapy and Pharmacology 6, 265 (1980); S. Salmon and D. D. Von Hoff, Seminars in Oncology, 8, 377 (1981)).
Compounds of formula I which have been found to have antitumor activity intercalate in vitro with DNA (this property is determined by viscometric methods using the procedure of W. D. Wilson et al., Nucleic Acids Research 4, 2697 (1954)) and a log P as calculated by the method of C. Hansch and A. Leo in Substituent Constants for Correlation Analysis in Chemistry and Biology, John Wiley and Sons, New York, 1979, lying in the range between -2.0 and +2.5.
As has been described above, the compounds of the present invention are useful for the treatment of animals (including humans) bearing susceptible tumors. The invention thus further provides a method for the treatment of tumors in animals, including mammals, especially humans, which comprises the administration of a clinically useful amount of compound of formula (I) in a pharmaceutically useful form, once or several times a day or other appropriate schedule, orally, rectally, parenterally, or applied topically.
In addition, there is provided as a further, or alternative, aspect of the invention, a compound of formula (I) for use in therapy, for example as an antitumor agent.
The amount of compound of formula (I) required to be effective as a biocidal agent will, of course, vary and is ultimately at the discretion of the medical or veterinary practitioner. The factors to be considered include the condition being treated, the route of administration, and nature of the formulation, the mammal's body weight, surface area, age and general condition, and the particular compound to be administered. A suitable effective antitumor dose is in the range of about 0.1 to about 120 mg/kg body weight, preferably in the range of about 1.5 to 50 mg/kg, for example 10 to 30 mg/kg. The total daily dose may be given as a single dose, multiple doses, e.g., two to six timers per day or by intravenous infusion for selected duration. For example, for a 75 kg mammal, the dose range would be about 8 to 9000 mg per day, and a typical dose would be about 2000 mg per day. If discrete multiple doses are indicated, treatment might typically be 500 mg of a compound of formula I given 4 times per day in a pharmaceutically useful formulation.
While it is possible for the active compound (defined herein as compound of formula (I), or ether, ester, or salt thereof) to be administered alone, it is preferable to present the active compound in a pharmaceutical formulation. Formulations of the present invention, for medical use, comprise an active compound together with one or more pharmaceutically acceptable carriers thereof and optionally other therapeutical ingredients. The carrier(s) must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
The present invention, therefore, further provides a pharmaceutical formulation comprising a compound of formula (I) (in the form of the free base, ether, or ester derivative or a pharmaceutically acceptable acid addition salt thereof) together with a pharmaceutically acceptable carrier therefore.
There is also provided a method for the preparation of a pharmaceutical formulation comprising bringing into association a compound of formula (I) an ether, ester, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier therefore.
While the antitumor activity of the compounds of formula (I) is believed to reside in the free base, it is often convenient to administer an acid addition salt of a compound of formula (I).
The formulations include those suitable for oral, rectal or parenteral (including subcutaneous, intramuscular and intravenous) administration. Preferred are those suitable for oral or parenteral administration.
The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active compound into association with a carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active compound into assocation with a liquid carrier or a finely divided solid carrier or both and then, if necessary, shaping the product into desired formulations.
Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, tablets or lozenges, each containing a predetermined amount of the active compound; as a powder or granules; or a suspension in an aqueous liquid or non-aqueous liquid such as a syrup, an elixir, an emulsion or a draught.
A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active compound in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered active compound with any suitable carrier.
A syrup may be made by adding the active compound to a concentrated, aqueous solution of a sugar, for example sucrose, to which may also be added any accessory ingredients. Such accessory ingredient(s) may include flavorings, an agent to retard crystallization of the sugar or an agent to increase the solubility of any other ingredient, such as a polyhydric alcohol for example glycerol or sorbitol.
Formulations for rectal administration may be presented as a suppository with a conventional carrier such as cocoa butter.
Formulations suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the active compound which is preferably isotonic with the blood of the recipient. Such formulations suitably comprise a solution of a pharmaceutically and pharmacologically acceptable acid addition salt of a compound of the formula (I) that is isotonic with the blood of the recipient. Thus, such formulations may conveniently contain distilled water, 5% dextrose in distilled water or saline and a pharmaceutically and pharmacologically acceptable acid addition salt of a compound of the formula (I) that has an appropriate solubility in these solvents, for example the hydrochloride, isethionate and methanesulfonate salts, preferably the latter.
Useful formulations also comprise concentrated solutions or solids containing the compound of formula (I) which upon dilution with an appropriate solvent give a solution suitable for parenteral administration as above.
In addition to the aforementioned ingredients, the formulations of this invention may further include one or more accessory ingredient(s) selected from diluents, buffers, flavoring agents, binders, surface active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
The following examples are provided by the way of illustration of the present invention and should in no way be construed as a limitation thereof.
GENERAL COMMENTS
All solvents were reagent grade and used without further purification with the following exceptions. THF was dried by distillation from Na/K alloy under nitrogen (N 2 ) and used immediately. Toluene (PhCH 3 ) was distilled from CaH 2 under N 2 and stored over 3 Å molecular sieves. Chemicals used were reagent grade and used without purification unless noted. The full name and address of the suppliers of the reagents and chemicals is given when first cited. After this, an abbreviated name is used.
Preparative HPLC was carried out on a Water's Prep LC/System 500A machine using two 500 g silica gel (SiO 2 ) cartridges unless otherwise noted. Plugs of SiO 2 used for purifications were "flash chromatography" silica gel (Merck & Co., Inc., Merck Chemical Division, Rahway, N.J., 07065 silica gel 60, 230-400 mesh). In this procedure, an appropriate volume sintered glass funnel was filled approximately 3/4 full with the SiO 2 and packed evenly by tapping the outside of the funnel. A piece of filter paper was then placed on top of the SiO 2 and a solution of the material to be purified applied evenly to the top. Gentle suction through a filter flask moved the eluting solvent through the plug rapidly. The appropriate size fractions were combined as needed and further manipulated.
General procedures are described in detail. Analogous procedures show melting point (mp), recrystallization solvents, and elemental analyses (all elements analyzing within a difference of ≦0.4% of the expected value). Any changes to the procedure such as solvent, reaction temperature, reaction time, or workup are noted.
NMR ( 1 H, 13 C), IR, MS data of all new products were consistent with the expected and proposed structures. The positions assigned to structural isomers were unequivocally determined by a number of NMR techniques. All final products were dried in a vacuum oven at 20 mm Hg pressure at the temperature indicated overnight (12-16 h). All temperatures are in degrees Celsius. Other abbreviations that were used: room temperature (RT), absolute (abs.), round bottom flask (RB flask), minutes (min), hours (h).


EXAMPLE 1
2-Methyl-2-((1-pyrenylmethyl)aminio)-1,3-propanediol
1A. 2-Methyl-2-((1-pyrenylmethyl)amino-1,3-propanediol hydrochloride
To a 2 L Erlenmeyer flask was added 1-pyrenecarbaldehyde (Aldrich Chemical Co., Milwaukee, WI, 53201, 115.1 g, 0.5 mol), 2-amino-2-methyl-1,3-propanediol (Aldrich, 52.57 g, 0.5 mol), p-toluenesulfonic acid.H 2 O (Eastman Kodak Co., Rochester, N.Y., 14650, 1 g, 5 mmol), and PhCH3 (500 mL). The mixture was warmed to reflux for a few minutes and H 2 O (˜10 mL) was driven off. The resulting yellow solutin was allowed to cool to RT, diluted with abs. EtOH (500 mL) and stirred overnight. NaBH 3 CN (Aldrich, 95%, 15.71 g, 0.25 mol) was added to the reaction. After the NaBH 3 CN dissolved, an indicator (bromocresol green, Eastman, 5 mg) was added. To the resulting blue solution was added 5 drops of 1M ethanolic HCl every 15 min. After 3 days the indicator turned green then yellow and a voluminous white precipitate was present in the flask. To the flask was then added 1M ethanolic HCl (50 mL). The reaction was diluted to 4 L with abs. Et 2 O and stirred for 1 h. The precipitate was then collected by filtration through a medium porosity glass fritted funnel, washed with Et 2 O (2 L), and pressed dry. The filter cake was washed thoroughly with 20% HCl (5×250 mL), pressed dry and then washed with CH 2 Cl 2 (4×500 mL), pressed and sucked dry. The white solid was dried at 60° overnight. The off-white crude material (149 g) was dissolved in hot H 2 O (2.5 L) containing 20 mL of conc. HCl and decolorized with 20 g of Calgon® (trademark of Calgon Corp., a subsidiary of Merck & Co., Pittsburgh, PA, 15230) brand of activated charcoal, filtered through a pad of Celite® (trademark of Johns Manville Co., Denver, CO, 80110) brand of filter-aid to give a total of 2.8 L of clear colorless solution. The volume of the solution was reduced to 1.8 L. The solution was allowed to cool to RT, and then was placed in a refrigerator overnight. The white solid which formed overnight was collected by filtration, dried overnight at 60°, and recrystallized from EtOH/Et 2 O to give 104 g (56%) of 2-methyl-2-((1-pyrenylmethyl)amino)-1,3-propanediol hydrochloride mp 231°-230°, (C, H, Cl, N).
1B. 2-Methyl-2-((1-pyrenylmethyl)amino-1,3-propanediol methanesulfonate
To a solution of 1A (35.58 g, 0.1 mol) in CH 3 OH (500 mL) was added 1N NaOH (110 mL) dropwise over 15 min. The mixture became hard to stir and was diluted with H 2 O (1.5 L). The white solid which formed was filtered and washed successively with warm H 2 O (3×500 mL), then CH 3 OH (200 mL), then Et 2 O (3×500 mL). It was then dried overnight in a vacuum. Final yield of material was 25.4 g (79.5%) which was used without further purification.
The free base (17.5 g, 54.8 mmol) was suspended in CH 3 OH, cooled, and treated slowly with methanesulfonic acid (Aldrich, 5.27 g, 3.56 mL, 54.8 mmol). The mixture was stirred at RT for 10 min, warmed to reflux, filtered through a sintered glass funnel, then diluted with Et 2 O (3.5 L). An oil formed which then crystallized within a few minutes. The solid was then filtered and recrystallized 2× from CH 3 OH/Et 2 O to give after drying 19.1 g (84.0%) of 2-methyl-2-((1-pyrenylmethyl)amino)-1,3-propanediol methanesulfonate mp 184°-186°, (C, H, N, S).
EXAMPLE 2
2-Methyl-2-((1-pyrenylmethyl)amino)propanol
2A. 2-Methyl-2-((1-pyrenylmethyl)amino)propanol hydrochloride
Using the reductive amination procedure outlined in 1A, 1-pyrenecarbaldehyde (Aldrich) and 2-methyl-2-amino-1-propanol (Aldrich) gave 2-methyl-2-((1-pyrenylmethyl)amino)propanol hydrochloride mp 253.5°-254° (dec), (95% EtOH), (C, H, Cl, N).
2B. 2-Methyl-2-((1-pyrenylmethyl)amino)propanol
Using the first part of the method in 1B, 2A gave 2-methyl-2((1-pyrenylmethyl)amino) propanol free base mp 135°-136°, (95% EtOH), (C, H, N).
EXAMPLE 3
3-((1-pyrenylmethyl)amino)propanol hydrochloride
Using the reductive amination procedure outlined in 1A, 1-pyrenecarbaldehyde (Aldrich) and 3-amino-1-propanol (Aldrich) gave 3-((1-pyrenylmethyl)amino)propanol hyrochloride mp 194°-195° (dec), (EtOH/Et 2 O), (C, H, Cl, N).
EXAMPLE 4
3-Methyl-2-((1-pyrenylmethyl)amino)butanol hydrochloride
Using the reductive aminatin procedure outlined in 1A, 1-pyrenecarbaldehyde (Aldrich) and 3-methyl-2-aminobutanol (Aldrich) gave 3-methyl-2-((1-pyrenylmethyl)amino)butanol hydrochloride mp 246°-248° (dec), (95% EtOH), (C, H, Cl, N).
EXAMPLE 5
2-Ethyl-2-((1-pyrenylmethyl)amino)-1,3-propanediol
5A. 2-Ethyl-2-((1-pyrenylmethyl)amino)-1,3-propanediol hydrochloride
Using the reductive amination procedure outlined in 1A, 1-pyrenecarbaldehyde (Aldrich) and 2-amino-2-ethyl-1,3-propanediol (Aldrich) gave 2-ethyl-2-((1-pyrenylmethyl)amino)-1,3-propanedol hydrochloride mp 225°-226.5° (dec), (EtOH/Et 2 O), (C, H, Cl, N).
5B. 2-Ethyl-2-((1-pyrenylmethyl)amino)-1,3-propanediol methanesulfonate
Using the procedure described in 1B, 5A gave 2-ethyl-2-((1-pyrenylmethyl)amino)-1,3-propanediol methanesulfonate mp 200°-201°, (CH 3 OH/Et 2 O), (C, H, N, S).
EXAMPLE 6
2-((1-Pyrenylmethyl)amino)butanol hydrochloride
Using the reductive amination procedure described in 1A, 1-pyrenecarbaldehyde (Aldrich) and 2-amino-1-butanol (Aldrich) gave 2-((1-pyrenylmethyl)amino)butanol hydrochloride mp 224°-225.5° (dec), (EtOH/Et 2 O), (C, H, Cl, N).
EXAMPLE 7
2-((1-Pyrenylmethyl)amino)propanol hydrochloride
Using the reductive amination procedure outlined in 1A, 1-pyrenecarbaldehyde (Aldrich) and 2-amino-1-propanol (Aldrich) gave 2-((1-pyrenylmethyl)amino)propanol hydrochloride mp 230°-232° (dec), (EtOH/Et 2 O), (C, H, Cl, N).
EXAMPLE 8
1-((1-pyrenylmethyl)amino)-2-propanol hydrochloride
Using the reductive amination procedure outlined in 1A, 1-pyrenecarbaldehyde (Aldrich) and dl-1-amino-2-propanol (Aldrich) gave 1-((1-pyrenylmethyl)amino)-2-propanol hydrochloride mp 217°-218° (dec), (abs. EtOH), (C, H, CL, N).
EXAMPLE 9
1-((1-Pyrenylmethyl)amino)-2-butanol hydrochloride
Using the procedure outlined in 1A, 1-pyrenecarbaldehyde (Aldrich) and 1-amino-2-butanol (Aldrich) gave 1-((1-pyrenylmethyl)amino)methyl)-2-butanol hydrochloride, mp 237°-238° (dec), (abs. EtOH), (C, H, Cl, N).
EXAMPLE 10
2-Hydroxymethyl-2-((1-pyrenylmethyl)amino)-1,3-propanediol hydrochloride
Using the reductive amination procedure outlined in 1A, 1-pyrenecarbaldehyde (Aldrich) and tris(hydroxymethyl)aminomethane (Aldrich) gave 2-hydroxymethyl-2-((1-pyrenylmethyl)amino)-1,3-propanediol hydrochloride mp 232°-234° (dec), (CH 3 OH/Et 2 O), (C, H, Cl, N).
EXAMPLE 11
2-((1-Pyrenylmethyl)amino)-1,3-propanediol hydrochloride
Using the reductive amination procedure outlined in 1A, 1-pyrenecarbaldehyde (Aldrich) and 2-amino-1,3-propanediol (Sigma Chemical Company, St. Louis, MO, 63178) gave 2-((1-pyrenylmethyl)amino)-1,3-propanediol hydrochloride mp 211°-213° (dec), (CH 3 OH/Et 2 O), (C, H, Cl, N).
EXAMPLE 12
2-(((1-Pyrenylmethyl)amino)methyl)-2-propanol hydrochloride
Using the reductive amination procedure outlined in 1A, 1-pyrenecarbaldehyde (Aldrich) and 1-amino-2-methyl-2-propanol (Aldrich) gave 2-(((1-pyrenylmethyl)amino)methyl-2-propanol hydrochloride, mp 225°-226.5° (dec), (abs. EtOH), (C, H, Cl, N).
EXAMPLE 13
2-((1-Pyrenylmethyl)amino)ethanol hydrochloride
Using the reductive amination procedure outlined in 1A, 1-pyrenecarbaldehyde (Aldrich) and 2-aminoethanol (Aldrich) gave 2-((1-pyrenylmethyl)amino)ethanol hydrochloride mp 202°-203° (dec), (95% EtOH) (C, H, Cl, N).
EXAMPLE 14
4-((1-Pyrenylmethyl)amino)-2-butanol hydrochloride
Using the reductive amination procedure outlined in 1A, 1-pyrenecarbaldehyde (Aldrich) and 4-amino-2-butanol (Aldrich) gave 4-((1-pyrenylmethyl)amino)-2-butanol hyrochloride mp 204°-206°, (EtOH/Et 2 O), (C, H, Cl, N).
EXAMPLE 15
2-Acetoxymethyl-1,3,-O-diacetyl-2-((1-pyrenylmethyl)amino)-1,3-propanediol
To a suspension of 2-hydroxymethyl-2-((1-pyrenylmethyl)amino)-1, 3 -propanediol hydrochloride (10, 2.50 g, 6.7 mmol) in 150 mL of dry THF was added 5 mL of acetylchloride (Aldrich, excess). The mixture was heated at reflux for 2 h, poured into 500 mL of cold 5% NaHCO 3 and then extracted with EtOAc (3×500 mL). The extracts were combined, washed with satd. NaCl solution, dried (K 2 CO 3 ) and concentrated to 200 mL. This solution was boiled with a small amount of decolorizing charcoal and applied to a small plug (50 g) of SiO 2 . Elution with 1 of EtOAc followed by concentration to 100 mL and dilution with 400 mL of hexane gave a crystalline product. This solid was collected by filtration and dried to give 2.73 g (88%) of 2-acetoxymethyl-1,3-O-diacetyl-2-((1-pyrenylmethyl)amino)-1,3-propanediol mp 150°-150.5°, (C, H, N).
EXAMPLE 16
2-Ethyl-2-((1-pyrenylmethyl)amino)-1,3-propanediol diacetate
Using the procedure described for 15, 2-ethyl-2-((1-pyrenylmethyl)amino)-1,3-propanediol hydrochloride (5A) gave 2-ethyl-2-((1-pyrenylmethyl)amino)-1,3-propanediol diacetate mp 106°-107°, (hexane), (C, H, N).
EXAMPLE 17
2-(((6-Bromo-1-pyrenyl)methyl)amino)-2-methyl-1,3-propanediol and 2-((8-Bromo-1-pyrenylmethyl)amino)-2-methyl-1,3-propanediol
17A. 6 and 8-Bromopyrene-1-carbaldehyde
1-Bromopyrene was prepared by the procedure of W. H. Gumprecht, Org. Syn. Coll. Vol. V, 147 (1973), and formylated using the procedure of A. Reiche et al., Chem. Ber. 93, 88 (1960) affording an approximately 1:1 ratio of 6- 8-bromopyrene-1-carbaldehydes mp 168°-181°, (PhCH 3 /CH 3 OH), (C, H, Br). This mixture was used without further purification.
17B. 2-((6-Bromo-1-pyrenylmethyl)amino)-2-methyl-1,3-propanediol hydrochloride and 2-((8-Bromo-1-pyrenylmethyl)amino)-2-methyl-1,3-propanediol hydrochloride
Using the reductive amination procedure described in 1A, the mixture of 6- and 8-bromopyrene-1-carbaldehydes (17A) and 2-amino-2-methyl-1,3-propanediol (Aldrich) gave a mixture of 2-((6-bromo-1-pyrenylmethyl)amino)-2-methyl-1,3-propanediol hydrochloride and 2-((8-bromo-1-pyrenylmethyl)amino)-2-methyl-1,3-propanediol hyrochloride (1:1) mp 219°-220°, (EtOH/Et 2 O), (C, H, Br, Cl, N).
EXAMPLE 18
2-Methyl-2-((1-pyrenylemthyl)amino)-1,3-propanediol diacetate
Using the procedure described for 15, 2-methyl-2-((1-pyrenylmethyl)amino)-1,3-propanediol hydrochloride (1A) gave 2-methyl-2-(1-pyrenylmethyl)amino)-1,3-propanediol diacetate mp 91°-92°, (hexane), (C, H, N).
EXAMPLE 19
2-Methyl-2-((4-pyrenylmethyl)amino)-1,3-propanediol
19A. 1,2,3,6,7,8-Hexahydro-4-pyrenecarbaldehyde
Using the formylation procedure of A. Reiche et al., Chem. Ber. 93, 88 (1960), 1,2,3,6,7,8 hexahydropyrene (Aldrich) gave 1,2,3,6,7,8-hexahydro-4-pyrenecarbaldehyde mp 102.5°-105°, (PhCH 3 /hexane), (C, H), (lit. mp 116°, J. -P. Hoeffinger et al., Bull. Soc. Chim. Fr. 3099 (1969)).
19B. 4-pyrenecarbaldehyde
1,2,3,6,7,8-Hexahydro-4-pyrenecarbaldehyde (19A, 11.81 g, 50 mmol) and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (Aldrich, 39.75 g, 0.175 mol) were refluxed for 4 h in 1 L of PhCH 3 . The reaction mixture was cooled and then filtered. The filtrate was washed with 2N NaOH (3×500 mL), satd. NaCl solution (2×500 mL), dried (Na 2 SO 4 ), and passed through a plug of SiO 2 (200 g). The solvent was then removed to give a bright yellow solid that was dried at 50° to give 8.91 g (77%) of 4-pyrenecarbaldehyde which was used without further purification. An analytical sample had mp 172°-174°, (CH 2 Cl 2 /hexane), (C, H), (lit. mp 177°-179°, Y. E. Gerasimenko and I. N. Shevcbuk, Zh. Org. Khim. 4 2198 (1968)).
19C. 2-Methyl-2-((4-pyrenylmethyl)amino)-1,3-propanedol hydrochloride
Using the reductive amination procedure outlined in 1A, 4-pyrenecarbaldehyde (19B) and 2-amino-2-methyl-1,3-propanedol (Aldrich) gave 2-methyl-2-((4-pyrenylmethyl)amino)-1,3-propanediol hydrochloride.1/4H 2 O mp 225°-227° (dec), (EtOH/Et 2 O), (C, H, Cl, N).
EXAMPLE 20
(+-)(2R*,3S*)-2-((1-Pyrenylmethylamino)-2-methyl-1,3-butanediol
20A. (+-)(2R*,3S*)-2-Methyl-2-nitro-1,3-butanediol and
20B. (+-)(2R*,3R*)-2-Methyl-2-nitro-1,3-butanediol
To a mixture of 2-nitro-1-propanol (Aldrich, 63.0 g, 0.060 mol) and acetaldehyde (Eastman, 39.6 g, 0.90 mol) cooled in an ice bath under N 2 was added cold H 2 O (40 mL) and calcium hydroxide (200 mg). The mixture was allowed to warm to RT over 2 h and the stirred for 68 h. The resulting solution was neutralized with excess solid CO 2 . The mixture was stirred for 1 h before filtration through a Millipore filter (Millipore Corp., Bedford, MA, 01730). The filtrate was then concentrated under vacuum at 35°. The residue, a viscous syrup which partially crystallized on drying under vacuum (0.1 mm, RT, 48 h), was trituarated with cold Et 2 O (35 mL). Solid white crystals which formed were collected by filtration, washed with cold Et 2 O (3×15 mL) and dried under vacuum (0.1 mm, RT) to give 34.1 g of material, judged by NMR to be (+)(2R*, 3S*)-2-methyl-2-nitro-1,3-propanediol (20A) (purity >97%, racemic). After recrystallization, the diastereomeric purity was >99%, mp 78.5°-81° (lit. 78°; cf. Beil 1, 482 in Henry, Bull. Soc. Chim. Fr. [3] 15, 1224), (C, H, N).
The original filtrate (including washing) was concentrated under vacuum to a pale yellow liquid which was subjected to flash chromatography as follows: The sample was mixed with hexane:EtOAc (2:1, 100 mL) and added to a column of dry SiO 2 (1.5 kg). The column was eluted with hexane:EtOAc (2:1, 12 L) then hexane:EtOAc (1:1, 6 L) while 500 mL fractions were collected. Appropriate fractions were combined. Pure product was found in the final 8 L; yield, 38.7 g of viscous syrup, judged by NMR to be a 1:1 mixture of the two racemic diastereomers (20A and 20B), (C, H, N).
This and another batch of the 1:1 diasteriomeric mixture (prepared as described above) were combined (67 g, total) and subjected to successive liquid-liquid partitioning between H 2 O and EtOAc to give pure samples (˜99% on the basis of NMR and HPLC (Hamilton PRP-1 column using 3.5% aqueous acetonitrile as the mobile phase)) of (+-)(2R*,3S*)-2-methyl-2-nitro-1,3-propanediol (20A) (24.9 g, k'=4.3, C, H, N) and (+-)(2R*,3R*)-2-methyl-2-nitro-1,3-butanediol (20B) (15.8 g, k'=2.1, C, H, N, a colorless, viscous liquid).
20C. (+-)(2R*,4S*,5R*)-4,5-dimethyl-5-nitro-2-phenyl-1,3-dioxane and
20D. (+-)(2R*,4S*,5S*)-4,5-dimethyl-5-nitro-2-phenyl-1,3-dioxane
The relative configurations of these two diasteriomeric pairs (20A and 20B) were unequivocably assigned on the basis of comparative NMR analysis of the respective cyclic acetals derived from benzaldehyde. Thus, (20A) (1.49 g, 0.01 mol) and benzaldehyde (Mallinckrodt, 1.06 g, 0.01 mol) were condensed in benzene in the presence of a catalytic amount of p-toluenesulfonic acid with azeotropic removal of water (according to the method of H. Piotrowska, B. Serafin and T. Urbanski, Tetrahedron 109, 379 (1963)). After successive washing with satd. NaHCO 3 solution, drying (MgSO 4 ), filtration, and removal of the benzene by rotary evaporation, a pale yellow solid was obtained. A solution of this product in ethanol at 0° C. provided an oil which was isolated by decanting the mother liquor and drying under vacuum (0.1 mm, RT). The yield was 1.48 g (62%) of (+-)(2R*,4S*,5R*)-4,5-dimethyl-5-nitro-2-phenyl-1,3-dioxane (20C) (C, H, N).
Similarly prepared from (20B) and benzaldehyde was (+-)(2R*,4S*,5S*)-4,5-dimethyl-5-nitro-2-phenyl-1,3-dioxane (20D) (74%) (C, H, N).
20E. (+-)(2R*,3R*)-2-Amino-2-methyl-1,3-butanediol acetate
To a solution of (+-)(2R*,3R*)-2-methyl-2-nitro-1,3-butanediol (20B, 22.1 g, 0.148 mol) in 95% EtOH (150 mL) was added glacial acetic acid (25 mL) and 10% Pd/C (MCB, 2.0 g). The reduction was carried out in a Parr apparatus at 50 psi of H 2 during a 48 h period at RT. The catalyst was removed by filtration through a Millipore® filter, and the solvent removed under vacuum (2 days). The viscous, colorless syrup was dissolved in abs. EtOH (30 mL). Dilution with abs. Et 2 O (300 mL) give a cloudy liquid which was placed in a refrigerator for two days. During this time, colorless crystals formed which were washed with Et 2 O and dried in a vacuum oven at RT for two days. The yield of (+-) (2R*,3R*)-2-amino-2-methyl-1,3-butanediol acetate was 25.6 g (97%) mp 117°-121°, (C, H, N).
20F. (+-)(2R*,3S*)-2-Amino-2-methyl-1,3-butanediol acetate
Using the procedure described for 20E, (+-)(2R*,3S*)-2-methyl-2-nitro-1,3-butanediol (20A) gave (+-)(2R*,3S*)-2-amino-2-methyl-1,3-butanediol acetate (93%) (C, H, N) mp 163°-165° C.
20G. (+-)(2R*,3S*)-2-((1-Pyrenylmethyl)amino)-2-methyl-1,3-butanediol hydrochloride
To a RB flask was added (+-)(2R*,3S*)-2-amino-2-methyl-1,3-butanediol acetate (20F) and an equimolar amount of sodium methoxide (MCB) and CH 3 OH (100 mL). After warming the solvent was removed by rotary evaporation and after addition of 1-pyrenecarbaldehyde (Aldrich) the reaction run following the normal reductive amination procedure outlined in 1A to give (+-)(2R*,3S*)-2-((1-pyrenylmethyl)amino)-2-methyl-1,3-butanediol hydrochloride mp 221°-222° (dec), (EtOH/Et 2 O), (C, H, Cl, N).
EXAMPLE 21
2-Ethoxymethyl-2-((1-pyrenylmethyl)amino)-1,3-propanediol
21A. 3,5-Diphenyl-7a(7H)-ethoxymethyl-1H,3H,5H-oxazolo(3,4-c)oxazole
A mechanically stirred 60% dispersion of NaH in mineral oil (Alfa, 34.0 g, 0.85 mol) was washed with dry hexane to remove the oil and suspended in dry DMF (300 mL). To the mixture was added a solution of 3,5-diphenyl-1H,3H,5H-oxazolo(3,4-c)oxazole-7a(7H)-methanol (208.2 g, 0.7 mol, prepared by the method of J. Pierce et al., J. Amer. Chem. Soc. 73 2595 (1951)) in dry DMF (300 mL) keeping the reaction mixture between 30°-35°. The salt suspension was stirred at RT for 60 min, diluted with dry DMF (200 mL) to facilitate stirring, cooled, then treated with ethyl iodide (Aldrich, excess) at such a rate that the reaction temperature was between 20°-35°. The mixture was stirred at RT for 2 h, then cautiously treated with absolute EtOH (30 mL). The resulting mixture was diluted with Et 2 O (2.5 L) and the resulting solids removed by filtration. The solvent was then removed using a rotary evaporator to give 299.5 g of a yellow oil containing both starting material and desired product. A solution of the oil in chloroform was mixed with SiO 2 (200 g) and the solvent removed. The solid was then added to a column of SiO 2 (800 g). Elution with the EtOAc/hexane (1:3.5) gave 139.7 g (61.3%) of 3,5-diphenyl-7a(7H)-ethoxymethyl-1H,3H,5H-oxazolo(3,4-c)oxazole. An analytical sample was obtained by recrystallization from hexane, mp 83.5°-85.°, (C, H, N). The bulk of the material was used without further purification.
21B. 2-Amino-2-ethoxymethyl-1,3-propanediol hydrochloride 1/4H 2 O
3,5-Diphenyl-7a(7H)-ethoxymethyl-1H,3H,5H-oxazolo(3,4-c)oxazole (21A, 136 g, 0.42 mol) was dissolved in 6N HCl (400 mL) and the resulting solution stirred 1.5 h at RT. After extraction with Et 2 O (2×200 mL) to remove benzaldehyde, the aqueous solution was concentrated on a rotary evaporator to give a colorless oil. This was cooled in an ice bath to facilitate crystallization. The solid which formed was slurried with cold CH 3 CN, filtered, then washed with Et 2 O and dried in a vacuum oven at RT to give 71 g (89%) of 2-amino-2-ethoxymethyl-1,3-propanediol hydrochloride.1/4H 2 O mp 78°-79°, (C, H, Cl, N).
21C. 2-Ethoxymethyl-2-((1-pyrenylmethyl)amino)-1,3-propanediol hydrochloride 1/3H 2 O
To a RB flask was added 2-amino-2-ethoxymethyl-1,3-propanediol hydrochloride.1/4H 2 O (21B) and an equimolar amount of sodium methoxide (MCB) and CH 3 OH (100 mL). After warming the solvent was removed by rotary evaporation and after addition of pyrene-1-carbaldehyde (Aldrich) the reaction run following the normal reductive amination procedure outlined in 20 G to give 2-ethoxymethyl-2-(((1-pyrenyl)methyl)amino)-1,3-propanediol hydrochloride.1/3H 2 O, mp 189°-190° (dec), (EtOH/Et 2 O), (C, H, Cl, N).
EXAMPLE 22
3-Methoxy-2-methyl-2-((1-pyrenylmethyl)amino)-1-propanol
22A. 4-Aza-3-hydroxymethyl-3-methyl-1-oxaspiro[4.5]decane
A solution of 2-amino-2-methyl-1,3-propanediol (Aldrich, 303.4 g, 3.0 mol), cyclohexanone (Fischer, 294.5 g, 3.0 mol) and PhCH 3 (400 mL) was refluxed for approximately 2 h with azeotropic removal of H 2 O. The material which crystallized from the PhCH 3 on cooling was recrystallized twice from hexane to give 444.4 g of 4-aza-3-hydroxymethyl-3-methyl-oxaspiro [4.5]decane (80%) mp 52°-54°, (C, H, N).
22B. 4-Aza-3-methoxymethyl-3-methyl-1-oxaspiro[4.5]decane
A mechanically stirred 60% dispersion of NaH in mineral oil (Alfa, 75 g, 1.9 mol) was washed with dry hexane to remove the oil and suspended in dry DMF (200 mL). To the mixture was added a solution of 4-aza-3-hydroxymethyl-3-methyl-1-oxaspiro[4.5]decane (22A, 27.8 g, 1.5 mol) in dry DMF (200 mL) keeping the reaction mixture temperature between 30°-35°. Small amounts of DMF were added as necessary to facilitate stirring. The mixture was stirred at RT for 1.5 h, then cooled and treated with methyl iodide (Fisher, 234.2 g, 102.7 mL, 1.65 mol) keeping the reaction temperature between 20°-30°. The mixture was stirred 2 H at RT and slowly treated with absolute EtOH (40 mL), then diluted with dry Et 2 O (3 L). The reaction mixture was filtered and the solvent removed by rotary evaporation. The residue was then fractionally distilled to give 209.7 g (70.3%) of 4-aza-3-methoxymethyl-3-methyl-1-oxaspiro[4.5]decane as a colorless liquid bp 114°/14 mm, (C, H, N).
22C. 2-Amino-3-methoxy-2-methyl-1-propanol
A solution of 4-aza-3-methoxymethyl-3-methyl-1-oxaspiro(4.5)decane (22B, 299 g, 1.5 mol) and 6N HCl (500 mL) was refluxed for 60 min. On cooling, two layers formed, the upper one containing cyclohexanone was removed by extraction with Et 2 O (2×400 mL). The lower aqueous layer was concentrated on a rotary evaporator to give a syrup which then was treated with excess 50% NaOH. The resulting slurry was extracted with Et 2 O/CH 2 Cl 2 (2:1, 4×500 mL), then with CH 2 Cl 2 (500 mL). The solvent was removed by rotary evaporation to give 198 g of pale oil. Fractional distillation of this oil gave 166 g (93%) of 2-amino-3-methoxymethyl-1-propanol as a colorless oil, bp 94° C./17 mm, (C, H, N).
22D. 3-Methoxy-2-methyl-2-((7-pyrenylmethyl)amino)-1-propanol methanesulfonate 1/3H 2 O
Using the reductive amination procedure outlined in 20G, pyrene-1-carbaldehyde (Aldrich) and 2-amino-3-methoxy-2-methyl-1-propanol (22C) gave after workup using the procedure outlined in 1B 3-methoxy-2-methyl-2-((1-pyrenylmethyl)amino)-1-propanol methanesulfonate.1/3H 2 O mp 158°-160°, (EtOH/Et 2 O), (C, H, N, S).
EXAMPLE 23
(1α,2β,3α)-2-((1-Pyrenylmethyl)amino)-1,3-cyclohexanediol methanesulfonate
23A. (1α,2β,3α)-2-Amino-1,3-cyclohexanediol acetate
This compound was prepared by the method of F. Lichtenthaler (Ber. 96, 851 (1963), mp 175°-177°, (C, H, N), (lit 178°-179°, F. Lichtenthaler, Ber. 96, 845 (1963).
23B. (1α,2β,3α)-2-((1-Pyrenylmethyl)amino)-1,3-cyclohexanediol methanesulfonate
To a RB flask was added (1α,2β,3α)-2-amino-1,3-cyclohexanediol acetate (23A) and an equimolar amount of NaOCH 3 and CH 3 OH (100 mL). After warming, the solvent was removed by rotary evaporation, and after addition of 1-pyrenecarbaldehyde (Aldrich) the reaction run following the normal reductive amination procedure outlined in 22D to give (1α,2β,3α)-2-((1-pyrenylmethyl)amino)-1,3-cyclohexanediol methanesulfonate mp 257°-258° (dec), (CH 3 OH/Et 2 O), (C, H, N, S).
EXAMPLE 24
Isopropyl-2-((1-pyrenylmethyl)amino)-1,3-propanediol
24A. 2-Isopropyl-2-nitro-1,3-propanediol
A solution of 2-methyl-1-nitropropane (38.7 g, 0.375 mol prepared by the procedure of N. Kornblum, B. Taube, and H. Ungnade, J. Am. Chem. Soc. 76, 3209 (1954) and NEt 3 (Eastman 3.79 g, 0.0375 mol) in CH 3 OH (50 mL) was added dropwise 37% aqueous formaldehyde solution (Mallinckrodt, 76.2 g, 0.938 mol), at a rate such that the reaction mixture temperature did not exceed 30°. After 72 h, the solution was concentrated under vacuum and the residue was dissolved in H 2 O (250 mL). The solution was continuously extracted for 1 h with CH 2 Cl 2 (1 L). The CH 2 Cl 2 solution was dried (MgSO 4 ), filtered, and concentrated to give 53.3 g (87%)of 2-isopropyl-2-nitro-1,3-propanediol a waxy, white solid mp 67°-72° (lit. mp 87°-88°, B. M. Vanderbilt and H. B. Hass, Ind. Eng. Chem. 32, 34 (1940). In our hands this procedure failed to give the desired compound).
24B. 2-Amino-2-isopropyl-1,3-propanediol acetate
Using the procedure in 20E, 2-isopropyl-2-nitro-1,3-propanediol gave a 98% yield of 2-amino-2-isopropyl-1,3-propanediol acetate mp 155°-155.5°. H. S. Broadbent et al., J. Heterocyclic Chem., 13, 337 (1975) report the synthesis of this compound as the free base (mp 70°-72°).
24C. 2-Isopropyl-2-((1-pyrenylmethyl)amino)-1,3-propanediol hydrochloride
Using the reductive amination procedure described for 20G, pyrene-1-carbaldehyde (Aldrich) and 2-amino-2-isopropyl-1,3-propanediol acetate (24B) gave 2-isopropyl-2-((1-pyrenylmethyl)amino)-1,3-propanediol hydrochloride mp 244°-245° (dec), (CH 3 OH/Et 2 O), (C, H, N, Cl).
EXAMPLE 25
2-(((3-Ethyl-1-pyrenyl)methyl)amino)-2-methyl-1,3-propanediol
25A. 3-Ethylpyrene-1-carboxaldehyde
1-Ethylpyrene (Cambridge Chemical, Inc., 55 g, 0.239 mol) was formylated by the procedure of A. Reiche et al., Chem. Ber. 93, 88 (1960). The isomeric aldehyde product mixture (48.2 g, 0.187 mol) (which could not be purified by chromatography on SiO 2 ) was treated with LiBH 4 (Alfa-Ventron, 2 g, 0.09 mol) in THF (800 mL). After 12 h, the reaction mixture was poured into ice water and acidified to pH=2 with 1N HCl. The isomeric alcohol mixture isolated (48 g, 0.18 mol) was chromatographed by preparative HPLC using CH 2 Cl 2 as the eluting solvent. A poorly resolved, 3-component band resulted. The first component to elute was isolated by front-shaving and purified by recycling. The purified component (8.5 g) was treated directly with BaMnO 4 (Aldrich, 15.75 g, 0.61 mol) in CH 2 Cl 2 (400 mL). After 3 h of refluxing, the mixture was filtered and the solvent removed to give the crude aldehyde. This was purified by preparative HPLC using CH 2 Cl 2 as the eluting solvent to give 4.38 g (7%) of 3-ethylpyrene-1-carboxaldehyde mp 134°-135.5°, (C, H), (CH 2 Cl 2 /hexane).
25B. 2-(((3-Ethyl-1-pyrenyl)methyl)amino)-2-methyl-1,3-propanediol methanesulfonate.3/10H 2 O
Using the reductive amination procedure outlined in 22D, 3-ethylpyrenecarboxaldehyde (25A) and 2-methyl-2-amino-1,3-propanediol (Aldrich) gave 2-(((3-ethyl-1-pyrenyl)methyl)amino)-2-methyl-1,3-propanediol methanesulfonate.3/10H 2 O mp 216°-219° (dec), (EtOH/Et 2 O), (C, H, N, S).
EXAMPLE 26
2-(((8-Ethoxy-1-pyrenyl)methyl)amino)-2-methyl-1,3-propanediol
26A. 8-Ethoxypyrene-1-carboxaldehyde
Using the method of E. Profft and R. Biela, Chem. Ber., 94, 2374-82, 1-ethoxypyrene (Cambridge Chemical, Inc., 25 g, 0.101 mol) yielded an insoluble red formylation complex that was filtered from the reaction mixture and hydrolyzed. The crude aldehyde obtained (mp 102°-122°) was recrystallized 2× from CH 2 Cl 2 /hexane to yield 7.52 g (27%) of 8-methoxypyrene-1-carboxaldehyde mp 135°-136°, (lit 135.5°-136.5°, E. Profft and R. Biela, Chem. Ber. 94, 2374-82), (C, H).
26B. 2-(((8-Ethoxy-1-pyrenyl)methyl)amino)-2-methyl-1,3-propanediol methanesulfonate
Using the reductive amination procedure described in 22D, 8-ethoxypyrene-1-carbaldehyde (26A) and 2-amino-2-methyl-1,3-propanediol (Aldrich) gave 2-(((8-ethoxy-1-pyrenyl)methyl)amino)-2-methyl-1,3-propanediol methanesulfonate mp 202°-203° (dec), (EtOH/Et 2 O), (C, H, N, S).
Antitumor Screening Results
Methods for evaluating the antitumor activity of these compounds are essentially those used in the Tumor Panel by the Development Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, A. Goldin, et al., Methods in Cancer Research, Vol. XVI, p. 165, Academic Press (1979). Some modifications in dose level and schedule have been made to increase the testing efficiency.
EXAMPLE 27
Lymphocytic Leukemia P388/0 Test
CD2-F 1 mice, of the same sex, weighing 20±3 g, are used for this test. Control and test animals are injected intraperitoneally with a suspension of ˜10 6 viable P388/0 tumor cells on day 0. In each test, several dose levels which bracket the LD 20 of the compound are evaluated; each dose level group contains 6 animals. The test compounds are prepared either in physiologic saline containing 0.05% Tween 80 or distilled water containing 5% dextrose and are administered intraperitoneally on days 1, 5, and 9 relative to tumor implant. Doses are on a mg/kg basis according to individual animals' body weights. The day of death for each animal is recorded, the median identified for each group and the ratios of median survival time for treated (T)/control (C) groups are calculated. The criterion for activity is T/C×100≧120%. Results of P388/0 testing are summarized in Table I below.

TABLE I______________________________________P388/0 SCREENING RESULTS T/C × 100%Compound of Optimal Dose (Excluding 30 DayExample No. (mg/kg) Survivors) LD.sub.20 A______________________________________2A 250 +168 1702B 450 +145 4503 120 +120 4504 200 +127 4505A 303 +240 2256 366 +125 4507 220 +125 6008 300 +128 6001A 300 +225 37510 198 +190 21511 300 +163 45013 220 +131 22015 555 +60 (500)16 1013 +185 (675)17B 250 +135 55718 300 +165 (300)19 40 +145 4520G 125 +177 12521C 168 +130 22522D 180 +130 13523B 18O +28O 180______________________________________ A. Values in parentheses are the highest nontoxic dose whether the LD.sub.20 was not determined.

EXAMPLE 28
Lymphocytic Leukemia L1210 Test
The protocol for this test is identical to that for P388/0, except that the number of L1210 cells implanted on day 0 is ˜105/mouse. The mouse CD-2-F1 strain is used, and the criterion for activity is T/C×100≧125%. Results of L1210 testing are summarized in Table II below.

TABLE II______________________________________Screening Results for L1210 T/C × 100% Dose Excluding 30 dayCompound No. (mg/kg) Survivors______________________________________1A 150 +129______________________________________

EXAMPLE 29
Melanotic Melanoma B16
B6C3-F1 mice of the same sex, weighing 20+3 g, are used for this test. A suspension of B16 cells is prepared from a non-necrotic portion of solid tumor tissue obtained from a passage mouse. One gram of tumour is homogenized in 9 mL ice-cold Earle's salts solution and filtered through 1000 mesh screen to remove debris. 0.5 mL of the resulting brei is injected intraperitoneally into each animal. Dosing is carried out as in the P388/0 and L1210 tests. Days of death are recorded for a 60 day period, and T/C ratio calculated as in the P388/0 and L1210 tests. The criterion for activity is T/C×100≧125%. The results of B16 testing are summarized below in Table III.

TABLE III______________________________________Screening Results for B16 Melanoma T/C × 100%Compound of Dose Excluding 60 dayExample No. (mg/kg) Survivors______________________________________5A 225 +15910 150 +133______________________________________

EXAMPLE 30
Lewis Lung Carcinoma Test
This tumor arose spontaneously in the lung of a C57B1/6 mouse and is maintained by subcutaneous passage in that strain. The solid tumor is excised aseptically and placed in sterile saline. Pieces of viable tumor tissue are minced finely with scissors and forced through a 200 mesh stainless steel screen to disaggregate the tumor cells into a suspension. 10 6 Viable cells and injected intravenously into the tail vein of BD-F 1 , mice of the same sex weighing 20±3 g. In each test, several dose levels which bracket the LD 20 for the compound are evaluated. Ten animals are included in each dose level group, and twenty animals in the untreated control group. The test compounds are prepared and aministered as in the P388/0 protocol. The day of death for each animal is recorded, the median identified for each group and the ratios of median survival time for treated (T)/control (C) groups are calculated. The criterion for activity is T/C×100≧140%. The results of Lewis Lung testing are summarized in Table IV.

TABLE IV______________________________________Screening Results for Lewis Lung T/C × 100% Dose Excluding 60 dayCompound No. (mg/kg) Survivors______________________________________1B 150 208______________________________________

EXAMPLE 31
Herpes simplex 1/vero Test
Antiviral testing against Herpes simplex 1/vero was done using plaque inhibition methods as outlined in P. Collins and D. J. Bauer, Proc. N.Y. Acad. Sci. 284, 49 (1977) and by plaque reduction methods as outlined in P. Collins and D. J. Bauer, J. Antimicrobiol Chemotherapy 3, Supplement A, 73, (1977). The column headings labeled Score, Toxicity, and Zone of Inhibition refer to the plaque inhibition screen while the IC 50 heading to the plaque reduction screen.

TABLE V______________________________________Results of Antiviral Screening Against Herpes simplex 1/veroCompound of Zone ofExample No. Score.sup.A Toxicity Inhibition.sup.B IC.sub.50 B______________________________________ 6 -2 Y16 -4 Y 4518 -3 Y 30(ST19)______________________________________ A. Score Code: 0 = no inhibition -1 = 1-25% inhibition -2 = 26-50% inhibition -3 = 51-75% inhibition -4 = 76-100% inhibition B. ST = slight toxicity, T = toxic, VT = very toxic

Antibacterial Screening
Antibacterial testing against Mycoplasma smegmatis (S3264) and Streptococcus pyogens (CN10) was done with slight modifications using standard agar dilution assays as outlined in Manual of Clinical Microbiology, Second Ed., E. H. Lennette, E. H. Spaulding and J. P. Truant Eds., American Society for Microbiology, Washington, DC, 1974.
EXAMPLE 32
Mycoplasma smegmatis Test

TABLE VI______________________________________Results of Antibacterial Screening AgainstMycoplasma smegmatis (S3264) Compound MIC Example No. (mg/L)______________________________________ 2A ≦5 3 <5 5A 3 6 10 7 ≦5 8 10 1A ≦5 9 10 10 >50 11 10 12 >50 13 5 14 10 15 ≦10 18 ≦10 19 10______________________________________

EXAMPLE 33
Streptococcus pyrogens Testing

TABLE VII______________________________________Results of Antibacterial Testing AgainstStreptococcus pyogenes (CN10) Compound of MIC Example No. (mg/L)______________________________________ 2A 10 3 10 5A 3 9 10 10 5 11 5 13 5 14 ≦5 18 30______________________________________

EXAMPLE 34
Candida albicans Testing
Antifungal testing against Candida albicans (CN1863) was done with slight modifications using a combination of broth and agar dilution assays as outlined in Laboratory Handbook of Medical Mycology, Chapter 6, pages 441-446, M. R. McGinnis, Academic Press, New York, NY, 1980.

TABLE VIII______________________________________Results of Antifungal Screening AgainstCandida albicans (CN1863) Compound of MIC Example No. (mg/L)______________________________________ 1A 50 2A 10 3 30 5A 50 6 50 7 50 8 50 9 10 10 >50 11 50 12 >50 13 10 14 50 15 >50 19 30______________________________________ Medium: Wellcotest* sensitivity test agar plus 7% lysed horse blood.

EXAMPLE 35
Trichomonas vaginalis Testing
Antiprotozoal testing against Trichomonas vaginalis was done using methods outlined by R. M. Michaels in Advances in Chemotherapy, 3, 39-108 (1968).

TABLE IX______________________________________Results of Antiprotozoal Testing AgainstTrichomonas vaginalis (in vitro)Compound of DoseExample No. (mg/L) Result.sup.A______________________________________1A 40 -42A 40 -33 6.25 -45A 40 -36 40 -49 40 -211 40 -4______________________________________ (Stenton or Modified Diamond's medium) A. Screen Code 0 = no inhibition -1 = 1-25% inhibition -2 = 26-50% inhibition -3 = 51-75% inhibition -4 = 76-100% inhibition

EXAMPLE 36
Nippostrongylus brasiliensis Testing
Anthelmintic testing against Nippostrongylus brasiliensis was done using methods as outlined in D. C. Jenkins, R. Armitage, and T. S. Carrington, Zetschrift fur Parasitenkunde 63, 261-269 (1980).

TABLE X______________________________________Results of Anthelmintic Screening AgainstNippostrongylus brasiliensis(Immature - free living stages) Compound of MIC Example No. (mg/L)______________________________________ 2A 10 3 1 4 10 5A 100 1A 50 9 50 14 50 13 50 11 ≧50 10 ≧50______________________________________

EXAMPLE 37
Eimeria tenella Testing
Antiprotozoal testing against Eimeria tenella was done using methods outlined in V. S. Latter and D. Wilson, Parasitology 79, 169 (1979).

TABLE XI______________________________________Results of Antiprotozoal Screening AgainstEimeria tenella (in vitro)Compound of DoseExample No. (mg/L) Result.sup.A______________________________________2A 5 -214 0.31 -213 5 -212 5 -411 5 -410 0.37 -4______________________________________ A. Screen Code 0 = no inhibition -1 = 1-25% inhibition -2 = 26-50% inhibition -3 = 51-75% inhibition -4 = 76-100% inhibition

EXAMPLE 38
Brugia pahangi Testing
Anthelmintic testing against Brugia pahangi was done using methods outlined in D. A. Denham et al., Transactions of the Royal Society of Tropical Medicine and Hygiene 73, 673-676 (1979).

TABLE XII______________________________________Results of Screening Against Brugia pahangi microfilaria (in vitro)Compound of Dose MICExample No. (mg/L) Result.sup.A (mg/L)______________________________________2A 3.1 -4 3.103 0.78 -4 0.784 12.5 -212 12.5 -2______________________________________ A. Screen Code 0 = no inhibition -1 = 1-25% inhibition -2 = 26-50% inhibition -3 = 51-75% inhibition -4 = 76-100% inhibition

EXAMPLE 39
LD 50 Tests

TABLE XIII______________________________________LD.sub.50 Values for Selected Compounds(IP single dose - CD.sub.1 Male Mouse) Compound of LD.sub.50 Example No. (mg/kg)______________________________________ 5A 160 6 350 1A 350 9 350 14 130 13 160 11 250 10 160______________________________________

EXAMPLE 40
Formulation Examples

______________________________________A. TABLET______________________________________Compound of Formula I 500.0 mgPregelatinized Corn Starch 60.0 mgSodium Starch Glycolate 36.0 mgMagnesium Stearate 4.0 mg______________________________________

The compound of formula (I) is finely ground and intimately mixed with the powdered excipients, pregelatinized corn starch and sodium starch glycolate. The powders are wetted with purified water to form granules. The granules are dried and mixed with the magnesium stearate. The formulation is then compressed into tablets weighing approximately 600 mg each.

______________________________________B. TABLET______________________________________Compound of formula (I) 500.0 mgCorn Starch 70.0 mgLactose 83.8 mgMagnesium Stearate 4.2 mgPolyvinylpyrrolidone 14.0 mgStearic Acid 28.0 mg______________________________________

The compound of formula (I) is finely ground and intimately mixed with the powdered excipients, corn starch and lactose. The powders are wetted with a solution of polyvinylpyrrolidone dissolved in purified water and denatured alcohol to form granules. The granules are dried and mixed with the powdered stearic acid and magnesium stearate. The formulation is then compressed into tablets weighing approximately 700 mg each.

______________________________________C. CAPSULES______________________________________Compound of formula (I) 500.0 mgCorn Starch 50.0 mgMagnesium Stearate 3.0 mg______________________________________

The finely divided compound of formula (I) is mixed with powdered corn starch and wetted with denatured alcohol to densify the powder. The dried powder is mixed with stearic acid and filled into hard-shell gelatin capsules.

______________________________________D. SYRUP______________________________________Compound of formula (I) 250.0 mgEthanol 250.0 mgGlycerin 500.0 mgSucrose 3,500.0 mgFlavoring Agent q.s.Coloring Agent q.s.Preserving Agent 0.1%Purified Water q.s. to 5.0 mL______________________________________

The compound of formula (I) is dissolved in the ethanol, glycerin, and a portion of the purified water. The sucrose and preserving agent are dissolved in another portion of hot purified water, and then the coloring agent is added and dissolved. The two solutions are mixed and cooled before the flavoring agent is added. Purified water is added to final volume. The resulting syrup is thoroughly mixed.

______________________________________E. IV INJECTION______________________________________Compound of formula (I) 5.0 mgGlycerin q.s. for isotonicityPreservative 0.1%Hydrochloric Acid or as needed forSodium Hydroxide pH adjustmentWater for Injection q.s. to 1 mL______________________________________

The compound of formula (I) and preservative is added to the glycerin and a portion of the water for injection. The pH is adjusted with hydrochloric acid or sodium hydroxide. Water for injection is added to final volume and solution is complete after thorough mixing. The solution is sterilized by filtration through a 0.22 micrometer membrane filter and aseptically filled into sterile 10 mL ampules or vials.